HACKENSACK, N.J., March 11, 2016 /PRNewswire/ -- Champions
Oncology (CSBR), a company engaged in the development of advanced
technology solutions and services to personalize the development
and use of oncology drugs, today announced it will be presenting at
the 28th Annual ROTH Capital Conference on Wednesday, March 16, 2016. The Conference will be
held at the Ritz Carlton in Dana Point,
California from March 13 – 16,
2016.
The Company's presentation, to be delivered by Chief Executive
Officer Joel Ackerman, is scheduled
for 10:30 a.m. Pacific Daylight
Time.
The presentation will be webcast and can be accessed at the
following link:
http://wsw.com/webcast/roth30/csbr
Mr. Ackerman will be available for one-on-one meetings during
the Conference. Investors interested in arranging a meeting with
Mr. Ackerman should contact their ROTH representative at (800)
933-6830.
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The company's technology
platform is a novel approach to personalizing cancer care based
upon the implantation of primary human tumors in immune-deficient
mice to create TumorGrafts that preserve the biological
characteristics of the original human tumor in order to determine
the efficacy of a treatment regimen. The company uses this
technology in conjunction with related services to offer solutions
for two customer groups: Personalized Oncology Solutions, in which
results help guide the development of personalized treatment plans,
and Translational Oncology Solutions, in which pharmaceutical and
biotechnology companies seeking personalized approaches to drug
development can lower the cost and increase the speed of developing
new drugs. For more information, please
visit www.championsoncology.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
(within the meaning of the Private Securities Litigation Act of
1995) that inherently involve risk and uncertainties.
Champions Oncology generally uses words such as "believe," "may,"
"could," "will," "intend," "expect," "anticipate," "plan," and
similar expressions to identify forward-looking statements.
One should not place undue reliance on these forward-looking
statements. The Company's actual results could differ
materially from those anticipated in the forward-looking statements
for many unforeseen factors. See Champions Oncology's Form
10-K for the fiscal year ended April 30,
2015 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are
made, and Champions Oncology's future results, levels of activity,
performance or achievements may not meet these expectations.
The Company does not intend to update any of the forward-looking
statements after the date of this press release to conform these
statements to actual results or to changes in Champions Oncology's
expectations, except as required by law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/champions-to-present-at-the-28th-annual-roth-capital-conference-on-march-16-2016-300234648.html
SOURCE Champions Oncology, Inc.